Hedeker Wealth LLC Raises Holdings in AbbVie Inc. $ABBV

Hedeker Wealth LLC increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 273.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,669 shares of the company’s stock after acquiring an additional 2,686 shares during the quarter. Hedeker Wealth LLC’s holdings in AbbVie were worth $681,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in ABBV. Brighton Jones LLC boosted its holdings in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after buying an additional 3,064 shares during the period. Jackson Creek Investment Advisors LLC purchased a new position in shares of AbbVie in the 1st quarter worth $688,000. Formidable Asset Management LLC grew its holdings in shares of AbbVie by 1.1% in the first quarter. Formidable Asset Management LLC now owns 10,590 shares of the company’s stock worth $2,219,000 after acquiring an additional 119 shares during the period. Finally, AMG National Trust Bank increased its position in AbbVie by 3.2% during the first quarter. AMG National Trust Bank now owns 22,776 shares of the company’s stock valued at $4,772,000 after acquiring an additional 711 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on ABBV. Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. BMO Capital Markets lifted their price target on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $232.43 on Friday. The firm has a market cap of $410.79 billion, a price-to-earnings ratio of 110.68, a P/E/G ratio of 1.42 and a beta of 0.50. The firm has a fifty day moving average price of $224.89 and a 200 day moving average price of $203.98. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio is currently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.